ATAI Investor Presentation Deck

We will deliver on our strategy through a robust pipeline with drug development programs across several mental health indications with large unmet need Program PCN-101/R-ketamine RL-007/Compound² GRX-917/Deuterated etifoxine DMX-1002/Ibogaine KUR-101/Deuterated mitragynine VLS-01/DMT EMP-01/MDMA derivative COMP360/Psilocybin³ COMP360/Psilocybin³ COMP360/Psilocybin³ Indication Treatment-Resistant Depression Cognitive Impairment Associated With Schizophrenia Generalized Anxiety Disorder Opioid Use Disorder Opioid Use Disorder Treatment-Resistant Depression Post-Traumatic Stress Disorder Treatment-Resistant Depression Post-Traumatic Stress Disorder Anorexia Nervosa Preclinical Phase 1 LIMITED TO EQUITY INTEREST Phase 2 Phase 3 Affiliate Company¹ Perception Neuroscience Recognify Life Sciences GABA Therapeutics DemeRx IB Kures Viridia Life Sciences Empath Bio Compass Pathways Compass Pathways Compass Pathways 06 Note: DMT = N,N-dimethyltryptamine; MDMA = 3,4-Methylenedioxymethamphetamine (1) Perception, Recognify, DemeRx IB, and Kures are all variable interest entities; GABA is a non-consolidated VIE with operational involvement through MSA model; EmpathBio and Viridia are wholly-owned subsidiaries; COMPASS Pathways is a non-controlling equity interests (2) RL-007 compound is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salts (3) Developing COMP360, a formulation of psilocybin, administered with psychological support from specially trained therapists Chart updated as of 9/30/2022

View entire presentation